Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Cell ; 142(6): 857-67, 2010 Sep 17.
Article in English | MEDLINE | ID: mdl-20817278

ABSTRACT

Alzheimer's Disease (AD) is complicated by pro-oxidant intraneuronal Fe(2+) elevation as well as extracellular Zn(2+) accumulation within amyloid plaque. We found that the AD ß-amyloid protein precursor (APP) possesses ferroxidase activity mediated by a conserved H-ferritin-like active site, which is inhibited specifically by Zn(2+). Like ceruloplasmin, APP catalytically oxidizes Fe(2+), loads Fe(3+) into transferrin, and has a major interaction with ferroportin in HEK293T cells (that lack ceruloplasmin) and in human cortical tissue. Ablation of APP in HEK293T cells and primary neurons induces marked iron retention, whereas increasing APP695 promotes iron export. Unlike normal mice, APP(-/-) mice are vulnerable to dietary iron exposure, which causes Fe(2+) accumulation and oxidative stress in cortical neurons. Paralleling iron accumulation, APP ferroxidase activity in AD postmortem neocortex is inhibited by endogenous Zn(2+), which we demonstrate can originate from Zn(2+)-laden amyloid aggregates and correlates with Aß burden. Abnormal exchange of cortical zinc may link amyloid pathology with neuronal iron accumulation in AD.


Subject(s)
Alzheimer Disease/pathology , Amyloid beta-Protein Precursor/antagonists & inhibitors , Amyloid beta-Protein Precursor/metabolism , Ceruloplasmin/antagonists & inhibitors , Zinc/metabolism , Alzheimer Disease/metabolism , Amino Acid Sequence , Amyloid beta-Protein Precursor/chemistry , Animals , Cell Line , Ceruloplasmin/chemistry , Ceruloplasmin/metabolism , Humans , Iron/metabolism , Mice , Sequence Alignment
2.
Free Radic Biol Med ; 46(10): 1328-37, 2009 May 15.
Article in English | MEDLINE | ID: mdl-19248830

ABSTRACT

alpha-Synuclein is the major component of the intracellular Lewy body inclusions present in Parkinson disease (PD) neurons. PD involves the loss of dopaminergic neurons in the substantia nigra and the subsequent depletion of dopamine (DA) in the striatum. DA can inhibit alpha-synuclein fibrillization in vitro and promote alpha-synuclein aggregation into soluble oligomers. We have studied the mechanism by which DA mediates alpha-synuclein aggregation into soluble oligomers. Reacting alpha-synuclein with DA increased the mass of alpha-synuclein by 64 Da. NMR showed that all four methionine residues were oxidized by DA, consistent with the addition of 64 Da. Substituting all four methionines to alanine significantly reduced the formation of DA-mediated soluble oligomers. The (125)YEMPS(129) motif in alpha-synuclein can modulate DA inhibition of alpha-synuclein fibrillization. However, alpha-synuclein ending before the (125)YEMPS(129) motif (residues 1-124) could still form soluble oligomers. The addition of exogenous synthetic YEMPS peptide inhibited the formation of soluble oligomers and resulted in the YEMPS peptide being oxidized. Therefore, the (125)YEMPS(129) acts as an antioxidant rather than interacting directly with DA. Our study defines methionine oxidation as the dominant mechanism by which DA generates soluble alpha-synuclein oligomers and highlights the potential role for oxidative stress in modulating alpha-synuclein aggregation.


Subject(s)
Dopamine/metabolism , Neurons/metabolism , Parkinson Disease/physiopathology , Protein Multimerization , alpha-Synuclein/metabolism , Amino Acid Motifs/genetics , Chromatography, High Pressure Liquid , Cloning, Molecular , Humans , Lewy Bodies/metabolism , Methionine/metabolism , Mutagenesis, Site-Directed , Neurons/ultrastructure , Oxidation-Reduction , Oxidative Stress , Parkinson Disease/pathology , Peptides/genetics , Peptides/metabolism , Protein Binding , Solubility , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , alpha-Synuclein/genetics
3.
J Mol Biol ; 377(1): 181-92, 2008 Mar 14.
Article in English | MEDLINE | ID: mdl-18237744

ABSTRACT

Alzheimer's disease (AD) is the most common form of dementia. Amyloid-beta (A beta) peptide, generated by proteolytic cleavage of the amyloid precursor protein, is central to AD pathogenesis. Most pharmaceutical activity in AD research has focused on A beta, its generation and clearance from the brain. In particular, there is much interest in immunotherapy approaches with a number of anti-A beta antibodies in clinical trials. We have developed a monoclonal antibody, called WO2, which recognises the A beta peptide. To this end, we have determined the three-dimensional structure, to near atomic resolution, of both the antibody and the complex with its antigen, the A beta peptide. The structures reveal the molecular basis for WO2 recognition and binding of A beta. The A beta peptide adopts an extended, coil-like conformation across its major immunodominant B-cell epitope between residues 2 and 8. We have also studied the antibody-bound A beta peptide in the presence of metals known to affect its aggregation state and show that WO2 inhibits these interactions. Thus, antibodies that target the N-terminal region of A beta, such as WO2, hold promise for therapeutic development.


Subject(s)
Amyloid beta-Peptides/chemistry , Amyloid beta-Peptides/immunology , Epitopes, B-Lymphocyte/chemistry , Epitopes, B-Lymphocyte/immunology , Immunodominant Epitopes/chemistry , Immunodominant Epitopes/immunology , Animals , Antibodies, Monoclonal/immunology , Complementarity Determining Regions/chemistry , Crystallography, X-Ray , Immunoglobulin Fab Fragments/chemistry , Immunoglobulin Fab Fragments/immunology , Ligands , Metals , Mice , Models, Molecular , Protein Structure, Secondary , Software , Surface Properties , Temperature
4.
J Mol Biol ; 367(1): 148-61, 2007 Mar 16.
Article in English | MEDLINE | ID: mdl-17239395

ABSTRACT

Alzheimer's disease (AD) is the major cause of dementia. Amyloid beta peptide (Abeta), generated by proteolytic cleavage of the amyloid precursor protein (APP), is central to AD pathogenesis. APP can function as a metalloprotein and modulate copper (Cu) transport, presumably via its extracellular Cu-binding domain (CuBD). Cu binding to the CuBD reduces Abeta levels, suggesting that a Cu mimetic may have therapeutic potential. We describe here the atomic structures of apo CuBD from three crystal forms and found they have identical Cu-binding sites despite the different crystal lattices. The structure of Cu(2+)-bound CuBD reveals that the metal ligands are His147, His151, Tyr168 and two water molecules, which are arranged in a square pyramidal geometry. The site resembles a Type 2 non-blue Cu center and is supported by electron paramagnetic resonance and extended X-ray absorption fine structure studies. A previous study suggested that Met170 might be a ligand but we suggest that this residue plays a critical role as an electron donor in CuBDs ability to reduce Cu ions. The structure of Cu(+)-bound CuBD is almost identical to the Cu(2+)-bound structure except for the loss of one of the water ligands. The geometry of the site is unfavorable for Cu(+), thus providing a mechanism by which CuBD could readily transfer Cu ions to other proteins.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/chemistry , Copper/chemistry , Amyloid beta-Peptides/metabolism , Copper/metabolism , Crystallography , Protein Conformation , Protein Structure, Tertiary
5.
Biochemistry ; 45(8): 2618-28, 2006 Feb 28.
Article in English | MEDLINE | ID: mdl-16489755

ABSTRACT

SorLA/LR11 is a sorting receptor that regulates the intracellular transport and processing of the amyloid precursor protein (APP) in neurons. SorLA/LR11-mediated binding results in sequestration of APP in the Golgi and in protection from processing into the amyloid-beta peptide (Abeta), the principal component of senile plaques in Alzheimer's disease (AD). To gain insight into the molecular mechanisms governing sorLA and APP interaction, we have dissected the respective protein interacting domains. Using a fluorescence resonance energy transfer (FRET) based assay of protein proximity, we identified binding sites in the extracellular regions of both proteins. Fine mapping by surface plasmon resonance analysis and analytical ultracentrifugation of recombinant APP and sorLA fragments further narrowed down the binding domains to the cluster of complement-type repeats in sorLA that forms a 1:1 stoichiometric complex with the carbohydrate-linked domain of APP. These data shed new light on the molecular determinants of neuronal APP trafficking and processing and on possible targets for intervention with senile plaque formation in patients with AD.


Subject(s)
Amyloid beta-Protein Precursor/metabolism , Membrane Transport Proteins/metabolism , Neurons/metabolism , Protein Transport/physiology , Receptors, LDL/metabolism , Amyloid beta-Protein Precursor/chemistry , Brain/metabolism , Cells, Cultured , Humans , LDL-Receptor Related Proteins , Membrane Transport Proteins/chemistry , Microscopy, Confocal , Models, Biological , Protein Binding , Protein Structure, Tertiary , Protein Transport/genetics , Receptors, LDL/chemistry , Surface Plasmon Resonance , Time Factors , Transfection
6.
J Mol Biol ; 357(2): 493-508, 2006 Mar 24.
Article in English | MEDLINE | ID: mdl-16436282

ABSTRACT

Proteolytic cleavage of the amyloid precursor protein (APP) by beta and gamma-secretases gives rise to the beta-amyloid peptide, considered to be a causal factor in Alzheimer's disease. Conversely, the soluble extracellular domain of APP (sAPPalpha), released upon its cleavage by alpha-secretase, plays a number of important physiological functions. Several APP fragments have been structurally characterized at atomic resolution, but the structures of intact APP and of full-length sAPPalpha have not been determined. Here, ab initio reconstruction of molecular models from high-resolution solution X-ray scattering (SAXS) data for the two main isoforms of sAPPalpha (sAPPalpha(695) and sAPPalpha(770)) provided models of sufficiently high resolution to identify distinct structural domains of APP. The fragments for which structures are known at atomic resolution were fitted within the solution models of full-length sAPPalpha, allowing localization of important functional sites (i.e. glycosylation, protease inhibitory and heparin-binding sites). Furthermore, combined results from SAXS, analytical ultracentrifugation (AUC) and size-exclusion chromatography (SEC) analysis indicate that both sAPPalpha isoforms are monomeric in solution. On the other hand, SEC, bis-ANS fluorescence, AUC and SAXS measurements showed that sAPPalpha forms a 2:1 complex with heparin. A conformational model for the sAPPalpha:heparin complex was also derived from the SAXS data. Possible implications of such complex formation for the physiological dimerization of APP and biological signaling are discussed in terms of the structural models proposed.


Subject(s)
Amyloid beta-Protein Precursor/chemistry , Heparin/metabolism , Protein Isoforms/chemistry , Protein Structure, Quaternary , Protein Structure, Tertiary , Alzheimer Disease/metabolism , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Cell Membrane/chemistry , Dimerization , Heparin/chemistry , Humans , Models, Molecular , Protein Binding , Protein Isoforms/genetics , Protein Isoforms/metabolism , Ultracentrifugation
7.
FASEB J ; 19(10): 1377-9, 2005 Aug.
Article in English | MEDLINE | ID: mdl-15946991

ABSTRACT

Dopamine (DA) and alpha-synuclein (alpha-SN) are two key molecules associated with Parkinson's disease (PD). We have identified a novel action of DA in the initial phase of alpha-SN aggregation and demonstrate that DA induces alpha-SN to form soluble, SDS-resistant oligomers. The DA:alpha-SN oligomeric species are not amyloidogenic as they do not react with thioflavin T and lack the typical amyloid fibril structures as visualized with electron microscopy. Circular dichroism studies indicate that in the presence of lipid membranes DA interacts with alpha-SN, causing an alteration to the structure of the protein. Furthermore, DA inhibited the formation of iron-induced alpha-SN amyloidogenic aggregates, suggesting that DA acts as a dominant modulator of alpha-SN aggregation. These observations support the paradigm emerging for other neurodegenerative diseases that the toxic species is represented by a soluble oligomer and not the insoluble fibril.


Subject(s)
Dopamine/pharmacology , Protein Folding , Sodium Dodecyl Sulfate/pharmacology , alpha-Synuclein/chemistry , Amyloid/chemistry , Benzothiazoles , Circular Dichroism , Ferric Compounds/pharmacology , Humans , Parkinson Disease/etiology , Protein Structure, Secondary , Thiazoles/analysis
8.
Article in English | MEDLINE | ID: mdl-16508101

ABSTRACT

Alzheimer's disease is thought to be triggered by production of the amyloid beta (Abeta) peptide through proteolytic cleavage of the amyloid precursor protein (APP). The binding of Cu2+ to the copper-binding domain (CuBD) of APP reduces the production of Abeta in cell-culture and animal studies. It is expected that structural studies of the CuBD will lead to a better understanding of how copper binding causes Abeta depletion and will define a potential drug target. The crystallization of CuBD in two different forms suitable for structure determination is reported here.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Protein Precursor/chemistry , Amyloid beta-Protein Precursor/metabolism , Copper/metabolism , Amyloid beta-Protein Precursor/isolation & purification , Base Sequence , Binding Sites , Cloning, Molecular , Crystallization , DNA Primers , Humans , Pichia , Protein Conformation , X-Ray Diffraction
9.
J Mol Biol ; 340(5): 1167-83, 2004 Jul 23.
Article in English | MEDLINE | ID: mdl-15236975

ABSTRACT

alpha-Synuclein is a pre-synaptic protein, the function of which is not completely understood, but its pathological form is involved in neurodegenerative diseases. In vitro, alpha-synuclein spontaneously forms amyloid fibrils. Here, we report that alphaB-crystallin, a molecular chaperone found in Lewy bodies that are characteristic of Parkinson's disease (PD), is a potent in vitro inhibitor of alpha-synuclein fibrillization, both of wild-type and the two mutant forms (A30P and A53T) that cause familial, early onset PD. In doing so, large irregular aggregates of alpha-synuclein and alphaB-crystallin are formed implying that alphaB-crystallin redirects alpha-synuclein from a fibril-formation pathway towards an amorphous aggregation pathway, thus reducing the amount of physiologically stable amyloid deposits in favor of easily degradable amorphous aggregates. alpha-Synuclein acts as a molecular chaperone to prevent the stress-induced, amorphous aggregation of target proteins. Compared to wild-type alpha-synuclein, both mutant forms have decreased chaperone activity in vitro against the aggregation of reduced insulin at 37 degrees C and the thermally induced aggregation of betaL-crystallin at 60 degrees C. Wild-type alpha-synuclein abrogates the chaperone activity of alphaB-crystallin to prevent the precipitation of reduced insulin. Interaction between these two chaperones and formation of a complex are also indicated by NMR spectroscopy, size-exclusion chromatography and mass spectrometry. In summary, alpha-synuclein and alphaB-crystallin interact readily with each other and affect each other's properties, in particular alpha-synuclein fibril formation and alphaB-crystallin chaperone action.


Subject(s)
Amyloid/chemistry , Amyloid/metabolism , Nerve Tissue Proteins/chemistry , Nerve Tissue Proteins/metabolism , alpha-Crystallin B Chain/metabolism , Amyloid/ultrastructure , Humans , Magnetic Resonance Spectroscopy , Mass Spectrometry , Microscopy, Electron , Nerve Tissue Proteins/ultrastructure , Protein Binding , Protein Denaturation , Spectrometry, Fluorescence , Synucleins , Temperature , alpha-Crystallin B Chain/chemistry , alpha-Crystallin B Chain/ultrastructure , alpha-Synuclein
10.
J Biol Chem ; 278(19): 17401-7, 2003 May 09.
Article in English | MEDLINE | ID: mdl-12611883

ABSTRACT

A major source of free radical production in the brain derives from copper. To prevent metal-mediated oxidative stress, cells have evolved complex metal transport systems. The Alzheimer's disease amyloid precursor protein (APP) is a major regulator of neuronal copper homeostasis. APP knockout mice have elevated copper levels in the cerebral cortex, whereas APP-overexpressing transgenic mice have reduced brain copper levels. Importantly, copper binding to APP can greatly reduce amyloid beta production in vitro. To understand this interaction at the molecular level we solved the structure of the APP copper binding domain (CuBD) and found that it contains a novel copper binding site that favors Cu(I) coordination. The surface location of this site, structural homology of CuBD to copper chaperones, and the role of APP in neuronal copper homeostasis are consistent with the CuBD acting as a neuronal metallotransporter.


Subject(s)
Amyloid beta-Protein Precursor/chemistry , Copper/chemistry , Neurons/metabolism , Alzheimer Disease/metabolism , Amino Acid Sequence , Amyloid beta-Protein Precursor/metabolism , Binding Sites , Biological Transport , Copper/metabolism , Humans , Molecular Sequence Data , Protein Binding , Protein Conformation
11.
J Neurosci ; 22(2): 365-76, 2002 Jan 15.
Article in English | MEDLINE | ID: mdl-11784781

ABSTRACT

The amyloid precursor protein (APP) of Alzheimer's disease (AD) has a copper binding domain (CuBD) located in the N-terminal cysteine-rich region that can strongly bind copper(II) and reduce it to Cu(I) in vitro. The CuBD sequence is similar among the APP family paralogs [amyloid precursor-like proteins (APLP1 and APLP2)] and its orthologs (including Drosophila melanogaster, Xenopus laevis, and Caenorhabditis elegans), suggesting an overall conservation in its function or activity. The APP CuBD is involved in modulating Cu homeostasis and amyloid beta peptide production. In this paper, we demonstrate for the first time that Cu-metallated full-length APP ectodomain induces neuronal cell death in vitro. APP Cu neurotoxicity can be induced directly or potentiated through Cu(I)-mediated oxidation of low-density lipoprotein, a finding that may have important implications for the role of lipoproteins and membrane cholesterol composition in AD. Cu toxicity induced by human APP, Xenopus APP, and APLP2 CuBDs is dependent on conservation of histidine residues at positions corresponding to 147 and 151 of human APP. Intriguingly, APP orthologs with different amino acid residues at these positions had dramatically altered Cu phenotypes. The corresponding C. elegans APL-1 CuBD, which has tyrosine and lysine residues at positions 147 and 151, respectively, strongly protected against Cu-mediated lipid peroxidation and neurotoxicity in vitro. Replacement of histidines 147 and 151 with tyrosine and lysine residues conferred this neuroprotective Cu phenotype to human APP, APLP2, and Xenopus APP CuBD peptides. Moreover, we show that the toxic and protective CuBD phenotypes are associated with differences in Cu binding and reduction. These studies identify a significant evolutionary change in the function of the CuBD in modulating Cu metabolism. Our findings also suggest that targeting of inhibitors to histidine residues at positions 147 and 151 of APP could significantly alter the oxidative potential of APP.


Subject(s)
Amyloid beta-Protein Precursor/metabolism , Copper/toxicity , Neurons/drug effects , Neurons/metabolism , Peptide Fragments/toxicity , Alzheimer Disease/metabolism , Amyloid beta-Protein Precursor/chemistry , Amyloid beta-Protein Precursor/toxicity , Animals , Binding Sites/genetics , Binding Sites/physiology , Caenorhabditis elegans , Cells, Cultured , Conserved Sequence/genetics , Conserved Sequence/physiology , Drosophila , Glycine/chemistry , Humans , Lipid Peroxidation/drug effects , Lipoproteins, LDL/drug effects , Lipoproteins, LDL/metabolism , Mice , Mutagenesis, Site-Directed , Neurons/cytology , Organometallic Compounds/chemistry , Oxidation-Reduction/drug effects , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Protein Structure, Tertiary/genetics , Protein Structure, Tertiary/physiology , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Recombinant Proteins/toxicity , Sequence Homology, Amino Acid , Species Specificity , Structure-Activity Relationship , Takifugu , Xenopus
SELECTION OF CITATIONS
SEARCH DETAIL
...